---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095775"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:49:28.126158+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics Q2 net loss $22.2M; cash runway into Q1 2025; positive CAN-2409 pancreatic data

## Summary
- Net loss of $22.2M in Q2 2024 vs $9.6M in Q2 2023; includes $13.7M non-cash warrant liability adjustment.
- Cash and cash equivalents $21.5M at June 30, 2024; expects funding operations into Q1 2025.
- CAN-2409 in pancreatic cancer: median OS 28.8 months vs 12.5 months control; 24-month survival 71.4% vs 16.7%.
- CAN-2409 in NSCLC: median OS 20.6 months in ICI-resistant patients; data presented at ASCO.
- Orphan drug designation from FDA for CAN-2409 (pancreatic) and CAN-3110 (rHGG); phase 3 prostate data expected Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-095775
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017024095775/0000950170-24-095775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017024095775/cadl-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095775
- JSON: https://secwatch.observer/filing/0000950170-24-095775.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095775.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.